Peter Lynch · Growth at a reasonable price (GARP)
Is Royalty Pharma plc (RPRX) a Peter Lynch Stock?
Some GARP characteristics, but growth or valuation is stretched.
58/100
Mitigé
2/6 critères validés
Les critères de Peter Lynch, appliqués à RPRX
PEG ≤ 1.0
clé2.33
EPS CAGR ≥ 15%
clé11.8%
Revenue CAGR ≥ 10%
1.0%
Net margin > 0
33.9%
Comment RPRX se classe selon d'autres stratégies
Données financières en direct
Cap. boursière
$33.03B
PER (TTM)
27.6x
ROIC (TTM)
8.43%
Marge brute
99.95%
Autres analyses Peter Lynch
Questions fréquentes
What is RPRX's Peter Lynch fit score?
RPRX scores 58/100 on our Peter Lynch fit engine. Some GARP characteristics, but growth or valuation is stretched.
Does Peter Lynch actually own RPRX?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends RPRX.
How often is this score updated?
RPRX's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Outil éducatif, pas un conseil en investissement. Les scores sont calculés à partir de données financières publiques selon les critères publiés de chaque stratégie d'investissement. Nous ne prétendons pas que Peter Lynch possède ou recommande RPRX personnellement.
